First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk
Open Access
- 31 May 2010
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 35 (6), 671-679
- https://doi.org/10.1002/uog.7559
Abstract
Objective To investigate the predictive value of the combination of first-trimester serum placental protein 13 (PP13), uterine artery Doppler pulsatility index (PI) and pulse wave analysis (augmentation index at a heart rate of 75 beats per min (AIx-75)), and to evaluate concurrent and contingent strategies using this combination for assessing the risk of pre-eclampsia in high-risk women. Methods In this nested case control study, serum PP13, uterine artery mean PI and AIx-75 were measured at between 11 + 0 and 13 + 6 weeks' gestation in women at increased risk of pre-eclampsia. For each case of pre-eclampsia (n = 42), five matched controls were randomly selected from the study group. Gestation specific multiples of the median (MoMs) were adjusted for body mass index, ethnicity, smoking, age and parity. MoMs were compared between cases and controls using the Wilcoxon rank sum test. Sensitivities and specificities were derived from receiver operating characteristics curves. Results Compared with controls, women who developed pre-eclampsia had lower PP13, higher uterine artery mean PI and higher AIx-75 (P PP13 --> mean PI) and (PP13 --> Alx-75 --> mean PI), with an 86% detection rate for false-positive rates of 9 and 10%, respectively. These two sequences would require 410 and 414 tests, respectively, compared with 756 tests in concurrent testing. Conclusion Combination of first-trimester PP13 uterine artery mean PI and pulse-wave analysis is promising for the prediction of pre-eclampsia in women at increased a-priori risk and may be useful in clinical practice. Contingency screening achieved similar detection rates to concurrent testing., but required almost 50% fewer tests, making it a more cost-effective option. Copyright (C) 2010 ISUOG. Published by John Wiley & Sons, Ltd.Keywords
This publication has 50 references indexed in Scilit:
- Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndromeVirchows Archiv, 2008
- First-trimester maternal serum PP13 in the risk assessment for preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2008
- Adverse Perinatal Outcomes and Risk Factors for Preeclampsia in Women With Chronic HypertensionHypertension, 2008
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJ, 2007
- Increased Apoptosis in First Trimester Extravillous Trophoblasts from Pregnancies at Higher Risk of Developing PreeclampsiaThe American Journal of Pathology, 2007
- Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factorAmerican Journal of Obstetrics and Gynecology, 2007
- Antiplatelet agents for preventing pre-eclampsia and its complicationsCochrane Database of Systematic Reviews, 2007
- Methods of assessment of the arterial pulse wave in normal human pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- Arterial Wave Reflections and Survival in End-Stage Renal FailureHypertension, 2001